Letter: double-dose intensification—a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply

Bella Ungar; Shomron Ben Horin; Xavier Roblin

doi:10.1111/apt.15139

Letter: double-dose intensification—a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply

Bella Ungar^*
, Shomron Ben Horin
, Xavier Roblin

^*Corresponding author for this work

Internal Medicine

CHU de Saint-Étienne

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	822-823
Number of pages	2
Journal	Alimentary Pharmacology and Therapeutics
Volume	49
Issue number	6
DOIs	https://doi.org/10.1111/apt.15139
State	Published - Mar 2019

Access to Document

10.1111/apt.15139

Cite this

@article{a8afcb4c1d2b4d8d9debe1dcaf2e9eb3,

title = "Letter: double-dose intensification—a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply",

author = "Bella Ungar and \{Ben Horin\}, Shomron and Xavier Roblin",

year = "2019",

month = mar,

doi = "10.1111/apt.15139",

language = "אנגלית",

volume = "49",

pages = "822--823",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Letter

T2 - double-dose intensification—a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply

AU - Ungar, Bella

AU - Ben Horin, Shomron

AU - Roblin, Xavier

PY - 2019/3

Y1 - 2019/3

UR - https://www.scopus.com/pages/publications/85062076802

U2 - 10.1111/apt.15139

DO - 10.1111/apt.15139

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 30811639

AN - SCOPUS:85062076802

SN - 0269-2813

VL - 49

SP - 822

EP - 823

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 6

ER -

Letter: double-dose intensification—a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply

Access to Document

Other files and links

Cite this